About phathom pharmaceuticals inc - PHAT
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
PHAT At a Glance
Phathom Pharmaceuticals, Inc.
100 Campus Drive
Florham Park, New Jersey 07932
| Phone | 1-877-742-8466 | Revenue | 175.11M | |
| Industry | Pharmaceuticals: Major | Net Income | -221,247,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 216.93% | |
| Fiscal Year-end | 12 / 2026 | Employees | 371 | |
| View SEC Filings |
PHAT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.908 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.473 |
| Enterprise Value to Sales | 9.531 |
| Total Debt to Enterprise Value | 0.353 |
PHAT Efficiency
| Revenue/Employee | 471,994.609 |
| Income Per Employee | -596,353.10 |
| Receivables Turnover | 2.241 |
| Total Asset Turnover | 0.549 |
PHAT Liquidity
| Current Ratio | 1.734 |
| Quick Ratio | 1.692 |
| Cash Ratio | 0.984 |
PHAT Profitability
| Gross Margin | 87.094 |
| Operating Margin | -91.363 |
| Pretax Margin | -126.347 |
| Net Margin | -126.347 |
| Return on Assets | -69.327 |
| Return on Equity | N/A |
| Return on Total Capital | -146.519 |
| Return on Invested Capital | -109.475 |
PHAT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 390.174 |
| Total Debt to Total Assets | 226.775 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 371.70 |